Literature DB >> 10637364

Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery.

G Trapani1, C Altomare, G Liso, E Sanna, G Biggio.   

Abstract

Propofol (2,6-diisopropylphenol) is becoming the intravenous anesthetic of choice for ambulatory surgery in outpatients. It is extensively metabolized, with most of the administered dose appearing in the urine as glucuronide conjugates. Favorable operating conditions and rapid recovery are claimed as the main advantages in using propofol, whereas disadvantages include a relatively high incidence of apnea, and blood pressure reductions. Besides a literature summary of the pharmacodynamics, pharmacokinetics, toxicology, and clinical use, this review provides a deeper discussion on the current understanding of mechanism of action and structure-activity relationships, and recent findings on drug delivery technologies as applied to the improvement of propofol formulations. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABAA receptors. Recent results from recombinant human GABAA receptor experiments and findings from the work exploring the effects at other receptors (e.g., glycine, nicotinic, and M1 muscarinic receptors) are reviewed. Studies showing its antiepileptic and anxiolytic properties are also discussed. The structure-activity relationships (SAR) of series of alkylphenols and p-X-substituted congeners have been reinvestigated. Interestingly, unlike the other congeners tested sofar, p-iodo-2,6-diisopropylphenol displayed anticonvulsant and anticonflict effects, but not sedative-hypnotic and anesthetic properties. Due to its high lipid-solubility, propofol was initially formulated as a solution with the surfactant Cremophor EL, but the occurrence of pain on injection and anaphylactoid reactions prompted to search for alternative formulations. Results from using cyclodextrins, water-soluble prodrugs, and adopting Bodor's approach to the site-specific chemical delivery system (CDS), as well as the advantages provided by computer-controlled infusion systems, are examined in some detail.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637364     DOI: 10.2174/0929867003375335

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  85 in total

1.  Potentiating action of propofol at GABAA receptors of retinal bipolar cells.

Authors:  Lan Yue; An Xie; Karol S Bruzik; Bente Frølund; Haohua Qian; David R Pepperberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-16       Impact factor: 4.799

2.  A Single phenylalanine residue in the main intracellular loop of α1 γ-aminobutyric acid type A and glycine receptors influences their sensitivity to propofol.

Authors:  Gustavo Moraga-Cid; Gonzalo E Yevenes; Günther Schmalzing; Robert W Peoples; Luis G Aguayo
Journal:  Anesthesiology       Date:  2011-09       Impact factor: 7.892

3.  Blood pressure-lowering effects of propofol or sevoflurane anaesthesia are not due to enhanced nitric oxide formation or bioavailability.

Authors:  Dimitrios Tsikas; Jens Jordan; Stefan Engeli
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

4.  Spontaneous activity does not predict morphological type in cerebellar interneurons.

Authors:  Shlomi Haar; Ronit Givon-Mayo; Neal H Barmack; Vadim Yakhnitsa; Opher Donchin
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

Review 5.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

6.  Ameliorating the adverse cardiorespiratory effects of chemical immobilization by inducing general anaesthesia in sheep and goats: implications for physiological studies of large wild mammals.

Authors:  Adian Izwan; Edward P Snelling; Roger S Seymour; Leith C R Meyer; Andrea Fuller; Anna Haw; Duncan Mitchell; Anthony P Farrell; Mary-Ann Costello; Shane K Maloney
Journal:  J Comp Physiol B       Date:  2018-09-19       Impact factor: 2.200

7.  The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase.

Authors:  Sachin Patel; Eric R Wohlfeil; David J Rademacher; Erica J Carrier; LaToya J Perry; Abhijit Kundu; J R Falck; Kasem Nithipatikom; William B Campbell; Cecilia J Hillard
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  Resuscitated sudden cardiac death in Andersen-Tawil syndrome.

Authors:  Kelly J Airey; Susan P Etheridge; Rabi Tawil; Martin Tristani-Firouzi
Journal:  Heart Rhythm       Date:  2009-08-29       Impact factor: 6.343

9.  4D-QSAR analysis of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the GABA(A) receptor.

Authors:  Matthew D Krasowski; Xuan Hong; A J Hopfinger; Neil L Harrison
Journal:  J Med Chem       Date:  2002-07-18       Impact factor: 7.446

10.  Propofol facilitates glutamatergic transmission to neurons of the ventrolateral preoptic nucleus.

Authors:  Ke Y Li; Yan-zhong Guan; Kresimir Krnjević; Jiang H Ye
Journal:  Anesthesiology       Date:  2009-12       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.